Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax Plus Azacitidine Versus Standard Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations Eligible for Intensive Treatment

NCT05904106 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT05904106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05904106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax Plus Azacitidine Versus Standard Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations Eligible for Intensive Treatment
Lead sponsor
Technische Universität Dresden
Phase
Phase 2
Overall status
Recruiting
Start date
April 7, 2024
Completion date
September 30, 2030
Enrollment
146 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia